| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 02/28/2002 | WO2002016392A1 Oestrogen-17-sulphamates as inhibitors of steroid sulphatase |
| 02/28/2002 | WO2002016382A1 Improved specificity in treatment of diseases |
| 02/28/2002 | WO2002016381A2 Composition and method for inhibiting platelet aggregation |
| 02/28/2002 | WO2002016370A1 1h-imidazopyridine derivatives |
| 02/28/2002 | WO2002016369A2 Novel macrocycles and uses thereof |
| 02/28/2002 | WO2002016368A1 Process for the preparation and purification of thiol-containing maytansinoids |
| 02/28/2002 | WO2002016365A1 Pyrazole compounds, pharmaceutical compositions, and methods for modulating or inhibiting erab or hadh2 activity |
| 02/28/2002 | WO2002016359A1 Fused pyrazole derivatives being protein kinase inhibitors |
| 02/28/2002 | WO2002016358A2 Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands) |
| 02/28/2002 | WO2002016355A2 Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic) acetylcholine receptor ligands |
| 02/28/2002 | WO2002016351A1 Quinazoline derivatives as kinase inhibitors |
| 02/28/2002 | WO2002016350A1 Amine derivatives |
| 02/28/2002 | WO2002016337A1 Tricyclic compounds and pharmaceutical compositions containing the same |
| 02/28/2002 | WO2002016332A1 Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists |
| 02/28/2002 | WO2002016331A1 Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists |
| 02/28/2002 | WO2002016326A1 Heterocyclic-hydroxyimino-fluorenes and their use for inhibiting protein kinases |
| 02/28/2002 | WO2002016324A1 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists |
| 02/28/2002 | WO2002016321A1 Prodrugs to nmda receptor ligands |
| 02/28/2002 | WO2002016313A2 Integrin receptor inhibitors |
| 02/28/2002 | WO2002015977A2 Methods and compositions for treating ige-related disease using nnt-1 inhibitors |
| 02/28/2002 | WO2002015959A2 Compounds and compositions for delivering active agents |
| 02/28/2002 | WO2002015941A1 A method for reducing stress-induced overproduction of neuropeptide y in an individual |
| 02/28/2002 | WO2002015935A1 Fibrinogen lowering agents |
| 02/28/2002 | WO2002015926A1 c-mpl LIGAND-CONTAINING MEDICINAL COMPOSITIONS FOR INCREASING PLATELETS AND ERYTHROCYTES |
| 02/28/2002 | WO2002015925A1 Methof of regulating apoptosis and apoptosis-regulatory polypeptide |
| 02/28/2002 | WO2002015920A2 Treatment of hyperproliferative diseases |
| 02/28/2002 | WO2002015909A1 Substituted piperidines as melanocortin receptor agonists |
| 02/28/2002 | WO2002015906A1 2-3-disubstituted quinuclidines as modulators of monoamine transporters and therapeutic and diagnostic methods based thereon |
| 02/28/2002 | WO2002015905A1 The use of histamine h3 receptor inverse agonists for the control of appetite and treatment of obesity |
| 02/28/2002 | WO2002015895A2 Alpha-difluoromethylornithine (dfmo) use in the human prostate |
| 02/28/2002 | WO2002015894A2 Use of vitamin d derivatives as bone resorption inhibitors |
| 02/28/2002 | WO2002015893A2 Treatment of wounds |
| 02/28/2002 | WO2002015891A2 Pharmaceutical combination of angiotensin ii antagonists and ace inhibitors |
| 02/28/2002 | WO2002015890A1 Transdermal therapeutic system |
| 02/28/2002 | WO2002015889A1 Transdermal therapeutic system for treating restless-legs-syndrome |
| 02/28/2002 | WO2002015886A2 Oral fast-melt dosage form of a cyclooxygenase-2 inhibitor |
| 02/28/2002 | WO2002015885A2 Oral fast-melt formulation of a cyclooxygenase-2 inhibitor |
| 02/28/2002 | WO2002015879A1 A method of treating a systemic disease |
| 02/28/2002 | WO2002015846A2 Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders |
| 02/28/2002 | WO2002009734A8 Sugar absorption inhibitors and process for producing the same |
| 02/28/2002 | WO2001095924A3 Method for treating a movement disorder |
| 02/28/2002 | WO2001087887A3 Neuroprotective and anti-proliferative compounds |
| 02/28/2002 | WO2001085779A3 Protein complexes and assays for screening anti-cancer agents |
| 02/28/2002 | WO2001085762A3 Cancer diagnosis and assays for screening anti-cancer agents |
| 02/28/2002 | WO2001085699A3 Prodrugs of hiv replication inhibiting pyrimidines |
| 02/28/2002 | WO2001085196A3 Cxcr4 antagonist treatment of hematopoietic cells |
| 02/28/2002 | WO2001083385A3 Devices and method for production of traceable immunizing drinking water, other liquids and gas |
| 02/28/2002 | WO2001081343A3 Compounds for treating fibromyalgia and chronic fatigue syndrome |
| 02/28/2002 | WO2001079271A9 Albumin fusion proteins |
| 02/28/2002 | WO2001079258A9 Albumin fusion proteins |
| 02/28/2002 | WO2001079167A3 Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis |
| 02/28/2002 | WO2001076530A3 Il-8 receptor antagonists |
| 02/28/2002 | WO2001075064A3 Method and materials relating to insulin-like growth factor binding protein-like polypeptides and polynucleotides |
| 02/28/2002 | WO2001070984A3 Anti-tissue factor antibodies with enhanced anticoagulant potency |
| 02/28/2002 | WO2001070255A3 Combined treatment with keratinocyte growth factor and epidermal growth factor inhibitor |
| 02/28/2002 | WO2001068852A3 Apolipoprotein-a-i regulation of t-cell signalling |
| 02/28/2002 | WO2001068654A3 Tubulin binding ligands and corresponding prodrug constructs |
| 02/28/2002 | WO2001064639A3 Pde iv inhibiting amides, compositions and pharmaceutical use |
| 02/28/2002 | WO2001053321A3 Use of trilostane and its derivatives, optionally in combination with tamoxifen or raloxifene in the treatment of estrogen-dependent cancers e.g. breast, prostate and uterus cancers |
| 02/28/2002 | WO2001049309A3 Combinations of growth factors and i: upa or i: mmp for the treatment of damaged tissue |
| 02/28/2002 | WO2001045685A3 Formulations of adenosine a1 agonists |
| 02/28/2002 | WO2001045661A3 Cosmetic and/or pharmaceutical preparations |
| 02/28/2002 | WO2001041769A3 Combination of cyamemazine and an atypical neuroleptic |
| 02/28/2002 | WO2001031029A3 Human sphingosine kinase gene |
| 02/28/2002 | WO2001030812A3 Activation of hcv-specific t cells |
| 02/28/2002 | WO2001027261A3 Conjugates between a peptides and a nucleic acid analog, such as a pna, lna or a morpholino |
| 02/28/2002 | WO2001017614A3 Methods and compositions containing succinimide or maleimide derivatives of antineoplastic agents |
| 02/28/2002 | WO2001005422A3 Use of a polypeptide for detecting, preventing or treating a pathological condition associated with a degenerative, neurological or autoimmune disease |
| 02/28/2002 | WO2001001970A3 New uses potassium channel openers, such as the treatment of epilepsy |
| 02/28/2002 | WO2000077037A3 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 02/28/2002 | WO2000073307A8 Substituted 8-phenylxanthines useful as antagonists of a2b adenosine receptors |
| 02/28/2002 | WO2000067746A8 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors |
| 02/28/2002 | WO2000040569A9 2-amino-benzoxazinone derivatives for the treatment of obesity |
| 02/28/2002 | US20020026060 RAR selective retinoid agonists |
| 02/28/2002 | US20020026050 Thrombin receptor antagonists |
| 02/28/2002 | US20020026034 3-aminoethyl-n-amidino-2,5-dihydropyrrole derivatives having arginine mimetic properties |
| 02/28/2002 | US20020025985 Apoptosis inhibitor |
| 02/28/2002 | US20020025981 Synergistic mixture of amlodipine and statins |
| 02/28/2002 | US20020025980 Single morphic forms of metalloproteinase inhibitors |
| 02/28/2002 | US20020025976 Thiazole compounds and pharmaceutical compositions for inhibiting protein kinases and methods for their use |
| 02/28/2002 | US20020025967 Antiserotinone agents |
| 02/28/2002 | US20020025961 Platelet ADP receptor inhibitors |
| 02/28/2002 | US20020025959 Heterocycle carboxamides as antiviral agents |
| 02/28/2002 | US20020025957 Anticoagulants, cardiovascular disorders |
| 02/28/2002 | US20020025956 Nervous system, psychological disorders |
| 02/28/2002 | US20020025955 Substituted lactams as inhibitors of A beta protein production |
| 02/28/2002 | US20020025950 Anticarcinogenic agents |
| 02/28/2002 | US20020025935 Antiinflammatory agents; autoimmune diseases; central nervous system disorders |
| 02/28/2002 | US20020025923 Antiinflammatory agents |
| 02/28/2002 | US20020025558 Human MAD proteins and uses thereof |
| 02/28/2002 | US20020025550 Methods for producing highly phosphorylated lysosomal hydrolases |
| 02/28/2002 | US20020025543 Methods and kits for diagnosing tumorigenicity and determining resistance to the antineoplastic effects of antiestrogen therapy |
| 02/28/2002 | US20020025342 Novel administration form comprising an acid-labile active compound |
| 02/28/2002 | US20020025317 For therapy and prophylaxis of pathological condition associated with expression of Interelukin-12 and/or Interleukin-18, including excessive or inappropriate amounts of those cytokines |
| 02/28/2002 | US20020025307 Gene therapy, testing |
| 02/28/2002 | US20020025304 Novel interferon for the treatment of multiple sclerosis |
| 02/28/2002 | DE10040105A1 Peptid- und Peptidmimetika-Derivate mit Integrin-Inhibitor-Eigenschaften Peptide and peptidomimetic derivatives having integrin inhibitor properties |
| 02/28/2002 | DE10040016A1 Neue beta-Amyloid Inhibitoren, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel New beta-amyloid inhibitors, processes for their preparation and their use as medicaments |
| 02/28/2002 | DE10038709A1 Substituierte und unsubstituierte Benzooxathiazole sowie daraus abgeleitete Verbindungen Substituted and unsubstituted Benzooxathiazole and compounds derived therefrom |
| 02/28/2002 | CA2678754A1 Process for the preparation and purification of thiol-containing maytansinoids |